Endourological Management of Stones During COVID19

March 22, 2022 updated by: Roxanne Teo

Definitive Endourological Interventions for Urolithiasis Management During COVID19- Outcomes From a Cohort Study

Guidelines for endourological procedures during COVID-19 have suggested deferring all elective procedures, while obstructed/ infected stones should undergo urgent decompression.

At our centre, screening protocols were implemented with prioritization strategies so that elective care could safely continue at deescalated rates. COVID or septic patients underwent emergency decompression, while non-COVID and non-septic patients underwent primary ureteroscopy (URS) or retrograde intrarenal surgery (RIRS).

We aim to report our experience with endourological surgery for stone disease during COVID-19.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

We conducted a retrospective review of a prospectively maintained database of all endourological surgeries for stones in our centre during the first wave of COVID19.

Study Type

Observational

Enrollment (Actual)

158

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Singapore
      • Singapore, Singapore, 609606
        • Ng Teng Fong General Hospital, Singapore

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All patients with obstructing urolithiasis who underwent decompression of ureteric stents, ureteroscopy or retrograde intrarenal surgery with laser lithotripsy during the period of study in our institution were included in the study

Description

Inclusion criteria

- all patient with urolithiasis who underwent endourological interventions during COVID19 pandemic

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients who underwent endourological surgery for urolithiasis during COVID19
Endourological surgery (including ureteral stent insertion, ureteroscopy, retrograde intrarenal surgery)
Procedure: Endourological surgery
Includes ureteral stent insertion, ureteroscopies and retrograde intrarenal surgeies

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length of hospital stay
Time Frame: From admission to discharge from hospital, up to 3 months
Length of hospital stay
From admission to discharge from hospital, up to 3 months
Complication rate
Time Frame: From admission up to 3 months post operatively
Complications as defined by Clavien Dindo classification system
From admission up to 3 months post operatively
Stone free rate
Time Frame: At follow up visit in clinic 3 months post procedure
At follow up visit in clinic 3 months post procedure

Secondary Outcome Measures

Outcome Measure
Time Frame
Readmission rate
Time Frame: From discharge up to three months post operatively
From discharge up to three months post operatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Roxanne Teo

Investigators

  • Principal Investigator: Chin Tiong Heng, Ng Teng Fong General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 23, 2020

Primary Completion (Actual)

August 31, 2020

Study Completion (Actual)

August 31, 2020

Study Registration Dates

First Submitted

March 13, 2022

First Submitted That Met QC Criteria

March 22, 2022

First Posted (Actual)

March 24, 2022

Study Record Updates

Last Update Posted (Actual)

March 24, 2022

Last Update Submitted That Met QC Criteria

March 22, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2020/01298

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe